AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01115062
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
Trial: NCT00883116
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01540344
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
Trial: NCT04536792
Drug: AG-946 Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
Trial: NCT01467362
Drug: V0034CR01B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
Trial: NCT01467362
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
Trial: NCT04140292
Drug: Photodynamic therapy (PDT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered.
Trial: NCT02698930
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
Trial: NCT00684944
Drug: TRx0014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsule, tid
Trial: NCT02684396
Drug: TAK-648 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-648 placebo-matching solution
Trial: NCT00065117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00065117
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04281524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of 70% 0.9% saline / 30% CSL312 diluent
Trial: NCT00214812
Drug: HEC placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02054754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02725411
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered Celecoxib 100 mg twice daily for 56 weeks
Trial: NCT01269476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volumes and frequency as active.
Trial: NCT02938520
Drug: ABC/DTG/3TC STR - Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Trial: NCT02938520
Drug: DTG Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Trial: NCT01921335
Drug: ARRY-380 Once Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Trial: NCT02243137
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration: one dose of Acetylsalicylic Acid (300mg)
Trial: NCT03393741
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Trial: NCT03393741
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is used to treat various stages of breast cancer.
Trial: NCT00206245
Drug: AZD0865
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00981227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral route
Trial: NCT01609582
Drug: TAK-875 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets
Trial: NCT00118365
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00572585
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00572585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01463982
Drug: Oratecan and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14
Trial: NCT01808248
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT01045512
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-80mg once daily
Trial: NCT00821977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003596
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00024349
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02245490
Drug: Matching placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01432028
Drug: Estradiol and Drospirenone
RxNorm normalized name: drospirenone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral estradiol 1mg and drospirenone 2 mg/day
Trial: NCT04479748
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid
Trial: NCT01699828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
Trial: NCT00653016
Drug: norelgestromin; ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01843309
Drug: Spironolactone 100mg
RxNorm normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01843309
Drug: Spironolactone 200mg
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01843309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00447161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00425451
Drug: PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01114581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as 2 tablets
Trial: NCT03568604
Drug: Prasterone
RxNorm normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6.5 vaginal insert prasterone (dehydroepiandrosterone)
Trial: NCT03485027
Drug: the rechallenge regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
Trial: NCT02700815
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02700815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02569307
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
Trial: NCT02569307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to TAU
Trial: NCT02569307
Drug: Minocycline Plus Omega-3 fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
Trial: NCT02246686
Drug: STW5-II (Iberogast N, BAY98-7410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application over 12 weeks 20 drops three time daily
Trial: NCT02246686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application over 12 weeks 20 drops three time daily
Trial: NCT01129323
Drug: Cyclophosphamide, Fludarabine, Rabbit ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
Trial: NCT00890942
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 1 ml IM
Trial: NCT01964872
Drug: Placebo: Parts 1a, 2, 3, and 4 (optional)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally matched to study drug
Trial: NCT01386034
Drug: Citrulline and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
Trial: NCT01941901
Drug: Calcium electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection, once only treatment.
Trial: NCT00115050
Drug: TMC114
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03445338
Drug: K0706
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study
Trial: NCT01093196
Drug: Cyclophosphamide, Prednisone, Lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
Trial: NCT01124435
Drug: Carboplatin plus Celecoxib
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
Trial: NCT01632163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection
Trial: NCT02899988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00176943
Drug: Aldara Cream 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03460990
Drug: VX-659/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.
Trial: NCT03460990
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received TEZ/IVA orally once daily in the morning.
Trial: NCT03460990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Trial: NCT03460990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
Trial: NCT00458445
Drug: SPD465
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00374049
Drug: MUC_1
RxNorm normalized name: Mucin-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
Trial: NCT01958060
Drug: Placebo to BI 1034020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous part
Trial: NCT01120899
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take 100 mg minocycline pills twice daily for 24 months.
Trial: NCT01602874
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Trial: NCT01602874
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Trial: NCT01602874
Drug: CAP: Ceftriaxone, plus if applicable oral clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Trial: NCT03510884
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT03510884
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT03510884
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT03510884
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT03510884
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT03510884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous injection
Trial: NCT00428818
Drug: trimethoprim-sulfamethoxazole or doxycycline
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03436953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01134198
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02111434
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Trial: NCT00658957
Drug: gentamicin-collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 cm sponge
Trial: NCT00658957
Drug: placebo collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 cm sponge
Trial: NCT03966950
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
Trial: NCT04472858
Drug: CS1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
Trial: NCT01636817
Drug: NNC0109-0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Trial: NCT01636817
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Trial: NCT03003364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a blinded syringe
Trial: NCT03244605
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Trial: NCT03244605
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
Trial: NCT01863186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Trial: NCT01427881
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV